Prophylaxis with Isavuconazole or Posaconazole Protects Immunosuppressed Mice from Pulmonary Mucormycosis

Antimicrob Agents Chemother. 2017 Apr 24;61(5):e02589-16. doi: 10.1128/AAC.02589-16. Print 2017 May.

Abstract

We assessed prophylactic or continuous therapy of isavuconazole, posaconazole, or voriconazole in treating pulmonary murine mucormycosis. In the prophylaxis studies, only isavuconazole treatment resulted in significantly improved survival and lowered tissue fungal burden of immunosuppressed mice infected with Rhizopus delemar. In the continuous treatment studies, isavuconazole and posaconazole, but not voriconazole, equally prolonged survival time and lowered tissue fungal burden compared to placebo-treated mice. These results support the use of isavuconazole and posaconazole in prophylaxis treatment.

Keywords: Rhizopus delemar; isavuconazole; mucormycosis; murine; posaconazole; prophylaxis; voriconazole.

MeSH terms

  • Animals
  • Antibiotic Prophylaxis / methods
  • Antifungal Agents / therapeutic use*
  • Disease Models, Animal
  • Immunosuppression Therapy
  • Lung Diseases, Fungal / drug therapy*
  • Lung Diseases, Fungal / prevention & control*
  • Mice
  • Mucormycosis / drug therapy*
  • Mucormycosis / prevention & control*
  • Nitriles / therapeutic use*
  • Pyridines / therapeutic use*
  • Rhizopus / drug effects
  • Triazoles / therapeutic use*
  • Voriconazole / therapeutic use*

Substances

  • Antifungal Agents
  • Nitriles
  • Pyridines
  • Triazoles
  • isavuconazole
  • posaconazole
  • Voriconazole